RNA Outsourcing Videos

1. Addressing Industry Challenges In mRNA Product Commercialization

   While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

2. Who's In Charge? How To Ensure Effective Trial Oversight, Leadership 3/19/2025

   Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.

3. The Conjugation Conundrum: The Realities Of Conjugated LNP Manufacturing 2/24/2026

   In this Advancing RNA Live clip, CMC Consultant Sujit Jain explains the numerous ways that adding targeting ligands “stress tests” the standard LNP manufacturing platform, as well as outlines which capabilities are most important for companies to consider when selecting an outsourcing partner for their active delivery strategies.

4. Maintaining A State Of Control: EM And DES In Biopharma 4/9/2026

   Partner with a proven team to streamline your facility validation and environmental monitoring programs with flexible, cGMP-compliant services and reliable on-site collection.

5. Mastering The Complexities Of Gene Therapy Document Writing 5/20/2025

   Gain the insight and strategic flexibility needed to confidently navigate the unique scientific, regulatory, and documentation challenges of gene therapy development.

6. Customized mRNA Processing For Improved Therapy Development And Manufacturing 2/13/2025

   Optimize mRNA development by learning key strategies for process refinement, critical component identification, and in-process analytics to enhance therapeutic production.

7. The Current State of CDMO Platforms For gRNA Production 4/29/2026

   Max De Long, April Sena, and Venkat Krishnamurthy share their perspectives on the current “health” of CDMO SPOS and enzymatic ligation platforms, while also highlighting the “red flags” to look out for when taking stock of a CDMOs capabilities. 

8. mRNA Capabilities 3/4/2025

   Discover how our advanced capabilities in Hopkinton, MA, are overcoming the challenges of large-scale RNA therapeutic manufacturing, enabling the efficient production of complex srRNA and mRNA therapies.

9. mRNA Manufacturing: In House Or Outsourced? 3/31/2022

   Speaking of outsourcing, Akhilesh Bhambhani, Sr. Director, Biologics Drug Product Development at Ultragenyx Pharmaceuticals and Roberta Duncan, VP and mRNA Program Lead at Seqirus share what they’re manufacturing in house, what they’re outsourcing, and why in this segment from our recent CMC, Scale Up, & The Road To mRNA Regulatory Approval event. 

10. mRNA's Impact On Cost And Capacity To Surge Biopharma Production 5/22/2023

    TFF Pharmaceuticals’ Kayla Hannon and University of Sheffield’s Dr. Zoltán Kis discuss the cost and capacity implications of therapeutic demand surges in this Surge Manufacturing for Biopharma Resilience segment.